Artiva Biotherapeutics Earnings Call Transcripts
Fiscal Year 2026
-
A novel NK cell therapy for RA is advancing, with upcoming efficacy data in late-line patients and a focus on deep B-cell depletion, safety, and scalability. The approach aims for durable, one-time treatment and first-mover advantage in a significant unmet need population.
-
Deep B-cell depletion is positioned as a transformative approach for autoimmune diseases, with a lead focus on refractory rheumatoid arthritis due to high unmet need and first-mover potential. Early data show strong efficacy, favorable safety, and scalable, community-friendly administration, with pivotal trial plans and FDA discussions set for 2026.
Fiscal Year 2025
-
A novel off-the-shelf NK cell therapy for autoimmune disease shows a strong safety profile and deep B cell depletion, with pivotal RA trial plans and a large market opportunity ahead. Cash reserves support operations into 2027.
-
AlloNK, an allogeneic NK cell therapy, is advancing in autoimmune diseases with a focus on rheumatoid arthritis due to its safety, scalability, and robust B cell depletion. Initial efficacy data in RA are expected in the first half of 2026, with a goal of durable responses in refractory patients.
-
AlloNK, a non-genetically modified NK cell therapy, showed a favorable safety profile and consistent, deep B-cell depletion in autoimmune patients, with no cell therapy-related toxicities and outpatient feasibility. The therapy targets refractory RA, aiming for robust efficacy and scalability, with pivotal trial discussions planned for next year.
-
The session highlighted a non-genetically modified NK cell therapy platform combined with monoclonal antibodies, emphasizing safety, scalable manufacturing, and community-setting compatibility. Key data on B cell depletion and safety will be shared by year-end, with a lead indication and efficacy results to follow.
-
Enhanced NK cell therapies show promising efficacy and safety in oncology, informing autoimmune trial design. Initial efficacy data for AlloNK in autoimmune is delayed to H1 2026 to ensure robust results, with a focus on patient selection, safety, and expanding access to community settings.
-
The conference highlighted the progress of an off-the-shelf NK cell therapy for autoimmune diseases, emphasizing its scalable manufacturing, favorable safety profile, and potential for community-based administration. Interim data and ongoing trials aim to demonstrate efficacy and position the therapy competitively in a crowded field.
-
AlloNK, a non-engineered NK cell therapy, is advancing in Phase I autoimmune trials with initial data expected soon. Prior NHL data show deep B cell depletion and strong outpatient potential, while the therapy aims to address unmet needs in autoimmune disease with a favorable safety profile.
Fiscal Year 2024
-
A novel NK cell platform is advancing in autoimmune trials, aiming for deep B-cell depletion and outpatient use with a favorable safety profile. Initial data from lupus and basket trials are expected in the first half of next year, with plans to expand indications and demonstrate broad efficacy.